Identification | Back Directory | [Name]
Rilotumumab | [CAS]
872514-65-3 | [Synonyms]
Rilotumumab Rilotumumab (anti-HGF) Research Grade Rilotumumab(DHD03702) |
Hazard Information | Back Directory | [Description]
Rilotumumab is an anti-HGF antibody that prevents ligand binding to MET and its activation. | [Clinical Use]
A phase I/II trial of rilotumumab in combination with erlotinib was evaluated in previously treated NSCLC patients with metastatic disease. The results indicated a favorable safety profile and success in terms of disease control rate. A phase Ib/II trial of rilotumumab or ganitumab in combination with etoposide and carboplatin or cisplatin was evaluated in extensive-stage SCLC patients. |
|
Company Name: |
Biolab Reagents
|
Tel: |
027-65279366 18162686757 |
Website: |
www.biolabreagent.com/ |
|